Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more
Market Cap & Net Worth: Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has a market capitalization of $42.29 Billion ($42.29 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #507 globally and #406 in its home market, demonstrating a -0.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alnylam Pharmaceuticals Inc's stock price $318.91 by its total outstanding shares 132623144 (132.62 Million).
Alnylam Pharmaceuticals Inc Market Cap History: 2015 to 2026
Alnylam Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $12.49 Billion to $42.29 Billion (13.61% CAGR).
Index Memberships
Alnylam Pharmaceuticals Inc is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$880.78 Billion | 4.78% | #5 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.16 Trillion | 3.65% | #6 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 1.88% | #8 of 976 |
|
NASDAQ Composite
IXIC
|
$33.26 Trillion | 0.13% | #80 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 2.73% | #6 of 263 |
Weight: Alnylam Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alnylam Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alnylam Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.20x
Alnylam Pharmaceuticals Inc's market cap is 14.20 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
168.09x
Alnylam Pharmaceuticals Inc's market cap is 168.09 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.97 Billion | $47.16 Million | -$410.11 Million | 105.29x | N/A |
| 2017 | $16.85 Billion | $89.91 Million | -$490.87 Million | 187.40x | N/A |
| 2018 | $9.67 Billion | $74.91 Million | -$761.50 Million | 129.09x | N/A |
| 2019 | $15.27 Billion | $219.75 Million | -$886.12 Million | 69.51x | N/A |
| 2020 | $17.24 Billion | $492.85 Million | -$858.28 Million | 34.97x | N/A |
| 2021 | $22.49 Billion | $844.29 Million | -$852.82 Million | 26.64x | N/A |
| 2022 | $31.52 Billion | $1.04 Billion | -$1.13 Billion | 30.38x | N/A |
| 2023 | $25.39 Billion | $1.83 Billion | -$440.24 Million | 13.88x | N/A |
| 2024 | $31.21 Billion | $2.25 Billion | -$278.16 Million | 13.88x | N/A |
| 2025 | $52.74 Billion | $3.71 Billion | $313.75 Million | 14.20x | 168.09x |
Competitor Companies of ALNY by Market Capitalization
Companies near Alnylam Pharmaceuticals Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Alnylam Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- Argen-X (F:1AE): Ranked #552 globally with a market cap of $38.55 Billion USD ( €37.56 Billion EUR).
- CSL Ltd (PINK:CSLLY): Ranked #589 globally with a market cap of $35.87 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #552 | Argen-X | F:1AE | $38.55 Billion | €614.20 |
| #589 | CSL Ltd | PINK:CSLLY | $35.87 Billion | $74.44 |
Alnylam Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Alnylam Pharmaceuticals Inc's market cap moved from $12.49 Billion to $ 42.29 Billion, with a yearly change of 13.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $42.29 Billion | -19.80% |
| 2025 | $52.74 Billion | +68.99% |
| 2024 | $31.21 Billion | +22.94% |
| 2023 | $25.39 Billion | -19.46% |
| 2022 | $31.52 Billion | +40.14% |
| 2021 | $22.49 Billion | +30.48% |
| 2020 | $17.24 Billion | +12.85% |
| 2019 | $15.27 Billion | +57.96% |
| 2018 | $9.67 Billion | -42.61% |
| 2017 | $16.85 Billion | +239.34% |
| 2016 | $4.97 Billion | -60.23% |
| 2015 | $12.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Alnylam Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $42.29 Billion USD |
| MoneyControl | $42.29 Billion USD |
| MarketWatch | $42.29 Billion USD |
| marketcap.company | $42.29 Billion USD |
| Reuters | $42.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.